Atom Investors’s Anavex Life Sciences AVXL Stock Holding History

Atom Investors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,484	Closed	-$52K	–	376
2020 Q3	$52K	Buy	+11,484	New	+$49.4K	0.01%	492

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Atom Investors's AVXL Position: Q4 2020 in Review

Atom Investors sold out of Anavex Life Sciences (AVXL) in Q4 2020, closing a stake of 11,484 shares — an estimated $52K sold.

Atom Investors first reported a position in AVXL in Q3 2020 and held it in 1 quarter. The position peaked at $52K in Q3 2020. 93 funds tracked by Wall St. Rank hold AVXL as of Q4 2020.

Atom Investors reported no remaining Anavex Life Sciences position as of Q4 2020 after selling out during the quarter.
Atom Investors sold 11,484 Anavex Life Sciences shares in Q4 2020, an estimated $52K.
Atom Investors first reported a position in Anavex Life Sciences in Q3 2020 and held it in 1 quarter.
Atom Investors's Anavex Life Sciences position peaked at $52K in Q3 2020.
93 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2020.

Based on Atom Investors's 13F filing for Q4 2020, filed 16 Feb 2021.